NIH | National Cancer Institute | NCI Wiki  

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

Version 1 Current »

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Amy Leblanc

Otridge, John (NIH/NCI) [C]



Kim, Erika (NIH/NCI) [E]


Sommers, Connie (NIH/NCI) [E]


X
Debbie Knapp
X
Toby Hecht

Ralph Parchment

Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

SharePoint Site

https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups

Outstanding Action Items

  • Kuffel, Gina (NIH/NCI) [C] to relay info to Debbie for cancer types of interest to request from FidoCure: Glioma, osteosarcoma, bladder cancer, mucosal and acral melanoma, mast cell tumor. Request overview of what they have in their DB.
  • Debbie to write invitation for Jaime Modiano
  • Revisit new steering committee members in September 

Agenda

ItemWhoTalking Points
Continue discussion of potential submission of FidoCure  Animal Health data

Kuffel, Gina (NIH/NCI) [C] , Debbie Knapp

  • We asked FidoCure if they had data on glioma, osterosarcoma, bladder cancer, mucosal and acral melanoma, and mast cell tumor.

    • Gerry Post replied “We do have data on osteosarcoma, mast cell tumors and some acral melanomas. As for gliomas and urothelial carcinomas, biopsies are much less common so we have less data.” Although he does not specify, I would think they would have lots of data on mucosal oral melanoma too.
    • If we want to pursue this further, I think Gerry would like a more specific request that he will then take to his board.
Potential collaboration with the Data for the Common Good (DCG) team and possibly a new working group

Kim, Erika (NIH/NCI) [E] 

  • DCG are interested in helping end users identify related cases between canine and pediatric oncology
    • Building consensus data standards between human and canine data elements
    • Mapping existing data elements in the ICDC to NCIT codes to facilitate the findability of canine data related to human data through platforms such as the Cancer Data Aggregator.   
DGAB Updates

Kuffel, Gina (NIH/NCI) [C] 

Recently Released

  • ORGANOIDS01
    • Approved by SAC on 9/22/22
    • “Characterization of healthy and diseased canine tissues and organoids"
    • Iowa State University
    • Status: Data has been loaded to the Dev and QA tiers, all files have been indexed by DCF team, testing is in progress

ICDC Studies in Active Submission

  • COTC021
    • Approved by SAC on 6/30/23
    • "Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma"
    • Dr. Amy LeBlanc
    • Status: Working with data submitters to provide AWS creds
BPSC Updates

Kuffel, Gina (NIH/NCI) [C] 

  • 2022 BPSC Review Article

    The manuscript entitled "Leading the Pack: Best Practices in Comparative Canine Cancer Genomics to Inform Human Oncology" has been published by the journal of Veterinary and Comparative Oncology. 

Upcoming Steering Committee Meeting

Ralph Parchment

  • Enter date: Wednesday October 18th

Minutes (Not Verbatim)

CS- At minimum we are interested in genomic data and clinical metadata as represented on the ICDC. 

TH - Series biopsy information as well.

EK - Sam from UChicago Data for the Common Good is aware of the ICDC and there are comparative studies of interest between canine and pediatric cancer.

Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).

2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.

3. Comparative analyses of canine and human. Examples include:

1. Search for conserved mutations between canine and human tumors

2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans

5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Action items

  • No labels